With a wealth of globally-competitive scientific discovery, Canada is primed to lead the life sciences world. To make this a reality, at adMare BioInnovations, we use our scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, robust ecosystems and industry-ready talent — and re-invest our returns back into the Canadian industry to ensure it is sustained for the long-term.
with our partners in government, academia, industry and the investment community, if we focus on these three things: building companies, building ecosystems, and building talent, we will realize our vision of Canadian life sciences leading the world.
June 07 2022
Find Therapeutics Inc. (Montreal, Quebec) and SATT Conectus (Strasbourg, France) have signed an exclusive worldwide license to develop a promising therapy for Multiple Sclerosis (MS) and Optic Neuritis (ON) based on a new class of compounds.
June 07 2022
FORUS Therapeutics Inc ("FORUS”), is pleased to announce that on May 31, 2022 XPOVIO® (selinexor) was authorized for sale by Health Canada in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.
June 01 2022
adMare is pleased to announce the appointment of Anie Perrault, LL.L, ASC as Vice President, Public Affairs and Communications.
adMare offers a tremendous opportunity to advance your career while making a significant contribution to our mission of building companies, ecosystems, and talent.
Looking to connect to Canada’s life sciences industry builders? The adMare Community is a vibrant digital ecosystem that brings together over 1,300 life science professionals, from students to CEOs, from Victoria to Charlottetown. Everyone is welcome to join, engage, explore, share, and contribute to Canadian life science leading the world.